Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]

18 Jun 2026 07:00 CEST

· Strong recruitment momentum demonstrated in 2026
· Year-to-date recruitment has already surpassed total enrollment for 2025

Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical
company developing Radspherin[®], a receptor-independent alpha-emitting therapy
to eradicate cancer cells in the abdominal cavity after surgery with a single,
targeted dose, today announces that its ongoing Phase 2 trial of Radspherin[®]
in patients with peritoneal metastases from ovarian cancer has reached the 50%
patient recruitment milestone.

A total of 54 patients have now been enrolled in the study, representing half of
the planned trial population. Recruitment momentum has accelerated significantly
in 2026, with 11 patients enrolled in the first quarter and 17 patients
recruited in the second quarter to date, marking the highest recruitment levels
achieved in the study so far. Year-to-date recruitment of 28 patients has
already surpassed total enrollment for 2025.

Four new sites have opened for recruitment in 2026 and in total ten hospitals
across the United States, Spain, Norway, Belgium, the United Kingdom and Italy
are currently active in the trial, and further site activations are ongoing to
support continued recruitment.

"Reaching the halfway point for recruitment in our Phase 2 trial is an important
milestone for Oncoinvent and reflects the strong commitment of investigators and
study sites," said Oystein Soug, CEO of Oncoinvent. "We are pleased to see the
steps taken to accelerate recruitment translating into the strong enrollment
momentum seen in 2026. Building on the encouraging safety profile and
preliminary efficacy signals observed in earlier studies, we look forward to
further evaluating Radspherin's potential to improve outcomes for patients with
peritoneal metastases from ovarian cancer, who have limited treatment options
following surgery."

The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled
study evaluating the efficacy and safety of Radspherin[®] in patients with
peritoneal metastases from ovarian cancer. The primary objective is to compare
progression-free survival between patients receiving Radspherin[®] following
complete surgical resection and pre-operative chemotherapy, and those receiving
standard of care treatment consisting of chemotherapy and surgery alone.

Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin[®] is
well tolerated, with no dose-limiting toxicity observed at the recommended dose
of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in
ovarian cancer have been published in the peer-reviewed journal Gynecologic
Oncology (http://www.sciencedirect.com/science/article/pii/S0090825825011023),
and results from the Phase 1/2a study in colorectal cancer have been published
in the peer-reviewed journals Journal of Surgical
Oncology (https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.27897) and
Frontiers in Medicine (https://www.oncoinvent.com/wp-content/uploads/Published
-30-days-DLT-Radspherin-fmed-10-1070362.pdf).

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com

Optimum Strategic Communications
Zoe Bolt, Elena Bates, Katherine Bliss
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).

More information:
Access the news on Oslo Bors NewsWeb site